Merck (MRK) Share-based Compensation (2009 - 2026)

Merck (MRK) has 18 years of Share-based Compensation data on file, last reported at $185.0 million in Q1 2026.

• Quarterly Share-based Compensation fell 5.13% year-over-year to $185.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $810.0 million (up 3.85% YoY) and the FY2025 annual result came in at $820.0 million, up 7.75% from the prior year.
• Share-based Compensation declined to $185.0 million in Q1 2026 per MRK's latest filing, from $205.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $216.0 million in Q2 2025 and bottomed at $120.0 million in Q1 2022.
• The 5-year median for Share-based Compensation is $176.0 million (2024), against an average of $173.6 million.
• The widest annual swing landed in 2023, when Share-based Compensation gained 23.36%; it then fell 5.13% in 2026.
• Tracing MRK's Share-based Compensation over 5 years: stood at $145.0 million in 2022, then increased by 15.17% to $167.0 million in 2023, then climbed by 11.98% to $187.0 million in 2024, then advanced by 9.63% to $205.0 million in 2025, then slipped by 9.76% to $185.0 million in 2026.
• Per Business Quant, the three latest MRK Share-based Compensation figures stand at $185.0 million (Q1 2026), $205.0 million (Q4 2025), and $204.0 million (Q3 2025).

Peer Comparison